Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5928724 | 0.87 | TSHR (0.68) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL25904137 | 0.84 | TSHR (0.65) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL449366 | 0.83 | L3MBTL1 (0.58) | TSHRTDP1KDM4EALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL7141648 | 0.81 | KDM4E (0.63) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL3860229 | 0.81 | TSHR (0.66) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL10362881 | 0.81 | KDM4E (0.76) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL15220622 | 0.81 | L3MBTL1 (0.55) | TSHRTDP1KDM4EALDH1A1KMT2A | |
| SCHEMBL7401969 | 0.80 | KMT2A (0.69) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL13936399 | 0.79 | KMT2A (0.73) | TSHRTDP1KDM4EALDH1A1HPGD | |
| SCHEMBL17115785 | 0.79 | TSHR (0.63) | TSHRTDP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025015167-A2 | ERASTIN KETONE ANALOGS AND USES THEREOF | EXARTA THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-2636669-B1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF AS FUNGICIDE | SINOCHEM CORP (CN) | 2015-10-21 | — | — | EP | disclosed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2636669-A1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF | Sinochem Corporation (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | BROX, OAT, CAT | TSHR 3562/4885TDP1 4236/4885KDM4E 2723/4885 |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | TSHR 518/4885TDP1 4440/4885KDM4E 3717/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | TSHR 518/4885TDP1 4440/4885KDM4E 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.